卡瑞丽珠长期治疗后发生大疱性类天疱疮一例  

Bullous pemphigoid occurred after long-term treatment with camrelizumab in a patient with oesophageal cancer:a case report

作　　者：郑淳之 张民阔 赛雯雯 曹园园 张朝霞 潘付堂[1,2] 杨宝琦 刘红[1,2] ZHENG Chunzhi;ZHANG Minkuo;SAI Wenwen;CAO Yuanyuan;ZHANG Zhaoxia;PAN Futang;YANG Baoqi;LIU Hong(Hospital for Skin Diseases,Shandong First Medical University,Jinan 250022,China;Shandong Provincial Institute of Dermatology and Venereology,Shandong Academy of Medical Sciences,Jinan 250022,China)

机构地区：[1]山东第一医科大学附属皮肤病医院,山东济南250022 [2]山东省皮肤病性病防治研究所,济南250022

出　　处：《中国麻风皮肤病杂志》2024年第6期422-424,共3页China Journal of Leprosy and Skin Diseases

基　　金：山东省皮肤性病学临床医学研究中心。

摘　　要：免疫检查点抑制剂(Immune Checkpoint inhibitors, ICI)为肿瘤的治疗带来了颠覆性的改革,但同时也导致较多免疫相关不良事件(immune-related adverse events, irAE)的发生。其中,大疱性类天疱疮(bullous pemphigoid, BP)是一种罕见的irAE,主要表现为红斑基础上出现水疱,疱壁紧张。本文报道1例发生于卡瑞丽珠长期治疗后的大疱性类天疱疮,并对ICI引起BP的诊断及治疗策略进行总结。Immune checkpoint inhibitors(ICIs)have brought about a disruptive change in the treatment of tumours,but have also led to a higher incidence of immune-related adverse events(irAEs).Among them,bullous pemphigoid(BP)is a rare irAE,which is mainly manifested by blisters with tense blister based on erythema.In this paper,we report a case of BP occurring after long-term treatment with camerelizumab and summarise the diagnosis and treatment strategy of ICI-induced BP.

关 键 词：PD-1抑制剂 卡瑞丽珠单抗 大疱性类天疱疮 

分 类 号：R758.66[医药卫生—皮肤病学与性病学]